Going forward, Sangamo will focus spending on developing epigenetic regulation therapies treating neurological diseases and novel adeno-associated virus (AAV) capsid delivery technologies. "The process of streamlining Sangamo's pipeline has been accelerated within today's challenging economic environment and we have had to make difficult decisions to defer further investments and seek collaboration partners or direct investment in both our Fabry gene therapy and CAR-Treg cell therapy programs," Sangamo CEO Sandy Macrae, MBChB, PhD said. The pause in spending on isaralgagene civaparvovec comes despite the company trumpeting promising clinical data from its ongoing first-in-human Phase I/II STAAR trial ( NCT04046224 ). Sangamo said all 25 patients dosed as of November 1 in the STAAR study have continued to show sustained, elevated α-Gal A levels, up to three years for the longest-treated patient.